Bionime (TPE:4737) Beginning Cash Position: NT$387 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4737 Bionime Corp TPE:4737
68 GF Score
Price NT$57.70
GF Value NT$53.93
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime Beginning Cash Position?

Bionime TPE:4737 +0.52% 68 Beginning Cash Position is NT$387 Mil as of Jun. 2026. GuruFocus rates TPE:4737 with a GF Score™ of 68/100 and a GF Value™ of NT$53.93 (Fairly Valued). The stock has 7 warning signs investors should review.

Bionime's Beginning Cash Position for the quarter that ended in Jun. 2026 was NT$387 Mil.

Bionime's quarterly Beginning Cash Position increased from Dec. 2025 (NT$307 Mil) to Mar. 2026 (NT$423 Mil) but then declined from Mar. 2026 (NT$423 Mil) to Jun. 2026 (NT$387 Mil).

Bionime's annual Beginning Cash Position increased from Dec. 2023 (NT$214 Mil) to Dec. 2024 (NT$392 Mil) but then declined from Dec. 2024 (NT$392 Mil) to Dec. 2025 (NT$321 Mil).

Bionime Beginning Cash Position Related Terms

Bionime Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Bionime's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Beginning Cash Position Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 343.25 253.09 214.49 391.82 321.23

Bionime Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 339.90 317.87 307.28 423.12 387.48
TPE:4737
68GF Score
Bionime Corp TPE:4737
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$387 Mil mean?
Bionime (TPE:4737) has a Beginning Cash Position of NT$387 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bionime and its competitors.
Is Bionime's Beginning Cash Position too high?
Bionime's current Beginning Cash Position is NT$387 Mil. Overall, Bionime has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Beginning Cash Position compare to ISRG and BDX?
Bionime's Beginning Cash Position of NT$387 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bionime and its competitors. Bionime's current Beginning Cash Position is NT$387 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$53.93, compared to a current price of NT$57.70 — trading 7% above its estimated fair value. The current Beginning Cash Position is NT$387 Mil. Bionime's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Bionime (TPE:4737), the current Beginning Cash Position is NT$387 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be overvalued. The current stock price of NT$57.70 is trading 7% above its estimated GF Value™ of NT$53.93. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Beginning Cash Position: NT$387 Mil
  • GF Value™: NT$53.93 vs. price of NT$57.70 (7% above fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
68GF Score

Get the complete analysis for TPE:4737

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$57.70
Price
NT$53.93
GF Value